분자진단 시장 : 시장 예측 - 제품별, 기술별, 분석 대상 물질별, 검사 유형별, 검체 유형별, 검사 시행 장소별, 용도별, 최종 사용자별 및 지역별 분석(-2034년)

According to Stratistics MRC, the Global Molecular Diagnostics Market is accounted for $21.6 billion in 2026 and is expected to reach $49.0 billion by 2034 growing at a CAGR of 10.8% during the forecast period. The Molecular Diagnostics Market represents a growing healthcare field that uses innovative molecular technologies to identify diseases by examining DNA, RNA, biomarkers, and other biological indicators. It covers solutions including PCR, sequencing-based platforms, and molecular assays applied in infectious disease testing, cancer diagnosis, and personalized healthcare approaches. Increasing focus on early detection, accurate diagnosis, and effective treatment selection is accelerating demand for molecular diagnostic tools globally. Expanding research activities, healthcare infrastructure improvements, and adoption of precision medicine are creating new opportunities for market participants. These technologies enhance clinical outcomes by providing rapid, sensitive, and dependable diagnostic information for diverse conditions.

Market Dynamics:

Driver:

Increasing Prevalence of Infectious Diseases

Increasing cases of infectious diseases worldwide are creating strong demand for molecular diagnostic solutions. These technologies help detect viruses, bacteria, and other pathogens with high precision and speed, allowing healthcare professionals to provide appropriate treatments and manage outbreaks effectively. Recent public health challenges have emphasized the importance of reliable molecular testing systems for monitoring and controlling disease spread. Investments by governments, healthcare institutions, and diagnostic laboratories in advanced testing infrastructure are increasing significantly. As the need for improved infection management, surveillance programs, and rapid pathogen identification grows, molecular diagnostics is becoming a critical component of global healthcare systems and disease prevention strategies.

Restraint:

High Cost of Molecular Diagnostic Technologies

Expensive molecular diagnostic platforms represent a significant challenge for market growth due to their high acquisition, maintenance, and operational expenses. Advanced testing equipment, consumables, and specialized laboratory requirements require substantial financial resources, which can restrict adoption among smaller healthcare providers and diagnostic centers. Additional costs related to workforce training and facility upgrades further impact implementation. Limited reimbursement policies and affordability concerns in emerging markets also reduce accessibility to these technologies. While ongoing innovations are helping decrease testing expenses, the considerable upfront investment needed for molecular diagnostic solutions remains a key factor slowing broader utilization across healthcare institutions worldwide.

Opportunity:

Expansion of Molecular Diagnostics in Emerging Markets

Developing economies present attractive opportunities for molecular diagnostics growth as healthcare systems continue to improve and modernize. Expanding medical infrastructure, increased awareness of advanced testing methods, and rising investments in healthcare technology are driving adoption in these regions. Governments are supporting initiatives focused on better disease detection, laboratory development, and public health monitoring, creating demand for molecular diagnostic platforms. Growing healthcare expenditures and larger patient populations further contribute to market potential. Manufacturers offering affordable, scalable, and efficient diagnostic solutions are well positioned to expand their presence. The increasing focus on improving healthcare accessibility will continue to support molecular diagnostics adoption across emerging markets.

Threat:

Regulatory Uncertainty and Changing Compliance Requirements

Evolving regulatory environments create obstacles for companies involved in molecular diagnostics development and commercialization. Manufacturers must comply with changing requirements related to safety, performance validation, clinical evidence, and data protection. Differences in approval standards across countries can complicate global expansion and increase administrative burdens. New regulatory expectations may require additional investments in testing, documentation, and product adjustments, leading to higher expenses and longer development timelines. Smaller market participants may find these requirements particularly challenging due to limited financial and technical resources. Regulatory uncertainty can therefore affect innovation speed, increase business risks, and influence the overall growth potential of molecular diagnostic companies.

Covid-19 Impact:

The COVID-19 outbreak had a major impact on the growth and development of the Molecular Diagnostics Market by creating unprecedented demand for fast and reliable diagnostic methods. PCR-based molecular testing became a primary solution for identifying SARS-CoV-2 infections and supporting global public health responses. The pandemic encouraged investments in laboratory infrastructure, diagnostic technologies, and healthcare research. Hospitals and testing centers increased their molecular testing capabilities to support screening, monitoring, and infection control efforts. While COVID-19 testing requirements have reduced compared with peak periods, the pandemic improved awareness of molecular diagnostics and accelerated their adoption for infectious diseases and other medical applications worldwide.

The Reagents & Kits segment is expected to be the largest during the forecast period

The Reagents & Kits segment is expected to account for the largest market share during the forecast period, because these components are fundamental to the functioning of molecular diagnostic workflows. They are widely used across PCR-based testing, sequencing applications, genetic analysis, and disease detection procedures. Rising demand for accurate diagnosis of infectious diseases, oncology conditions, and inherited disorders is increasing the utilization of molecular diagnostic kits and reagents. Their recurring consumption, continuous innovation in assay technologies, and broad applicability across healthcare settings contribute to segment growth. Additionally, increasing clinical testing volumes and expanding research applications are expected to maintain strong demand for reagents and kits in the molecular diagnostics industry.

The Pharmacogenomics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Pharmacogenomics segment is predicted to witness the highest growth rate, due to the increasing adoption of personalized medicine and targeted therapies. Molecular diagnostic technologies are enabling healthcare providers to analyze genetic variations that influence individual responses to medications, helping optimize treatment selection and improve patient outcomes. Growing demand for precision healthcare, advancements in genomic research, and increased integration of genetic testing into clinical decision-making are accelerating the adoption of pharmacogenomics solutions. Pharmaceutical companies are also utilizing pharmacogenomic testing during drug development and clinical trials to enhance therapeutic effectiveness. These factors are expected to drive rapid expansion of this segment within the molecular diagnostics market.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by its well-developed healthcare ecosystem, advanced diagnostic capabilities, and strong innovation environment. The region experiences high adoption of molecular testing solutions due to significant investments in genomic research, biotechnology advancements, and modern laboratory infrastructure. Increasing utilization of precision medicine, cancer testing, infectious disease diagnostics, and early detection methods is driving demand for molecular diagnostic technologies. Supportive healthcare frameworks, reimbursement availability, and strong industry participation further enhance market growth. Moreover, ongoing research initiatives and strategic collaborations among diagnostic providers and healthcare institutions continue to reinforce North America's dominance in the global molecular diagnostics industry.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to increasing healthcare investments, expanding diagnostic infrastructure, and rising adoption of advanced testing technologies. The region is experiencing growing demand for early disease detection, infectious disease monitoring, oncology diagnostics, and genetic testing solutions. Improving healthcare access, increasing awareness of precision medicine, and supportive government initiatives are encouraging the adoption of molecular diagnostic platforms. Additionally, the presence of a large patient population, rising prevalence of chronic and infectious diseases, and growing biotechnology activities are creating significant opportunities for market expansion across emerging economies in the Asia-Pacific region.

Key players in the market

Some of the key players in Molecular Diagnostics Market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Bio-Rad Laboratories, Inc., QIAGEN N.V., Siemens Healthineers AG, Hologic, Inc., Becton, Dickinson and Company (BD), Illumina, Inc., Agilent Technologies, Inc., Revvity, Inc., bioMerieux SA, Sysmex Corporation, Seegene Inc., Exact Sciences Corporation, Guardant Health, Inc. and DiaSorin S.p.A.

Key Developments:

In May 2026, QIAGEN partnered with Inpeco to advance automated molecular diagnostic workflows for QuantiFERON latent tuberculosis (TB) testing.

In January 2026, hermo Fisher Scientific announced a strategic collaboration with NVIDIA to combine AI technologies with laboratory instruments, software, and workflows.

Products Covered:

• Reagents & Kits
• Instruments
• Software & Services

Technologies Covered:

• Polymerase Chain Reaction (PCR)
• Isothermal Nucleic Acid Amplification (INAAT)
• Next-Generation Sequencing (NGS)
• Sanger Sequencing
• Microarrays
• In Situ Hybridization (ISH)
• Transcription-Mediated Amplification (TMA)
• CRISPR-Based Molecular Diagnostics

Analyses Covered:

• DNA
• RNA
• DNA & RNA

Test Types Covered:

• Qualitative Tests
• Quantitative Tests

Sample Types Covered:

• Blood
• Plasma & Serum
• Tissue
• Urine
• Saliva
• Nasopharyngeal & Oropharyngeal Swabs
• Sputum
• Stool
• Cerebrospinal Fluid (CSF)
• Other Clinical Specimens

Testing Locations Covered:

• Central Laboratory Testing
• Point-of-Care (POC) Testing
• Home-Based Testing

Applications Covered:

• Infectious Disease Diagnostics
• Oncology
• Genetic Disease Testing
• Reproductive Health Testing
• Blood Screening
• Pharmacogenomics
• Neurological Disorders
• Cardiovascular Diseases
• Respiratory Diseases
• Gastrointestinal Diseases
• Endocrine & Metabolic Disorders
• Transplant Diagnostics
• Other Clinical Applications

End Users Covered:

• Hospitals
• Clinical Laboratories
• Reference Laboratories
• Diagnostic Centers
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Public Health Laboratories
• Blood Banks
• Other End Users

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Molecular Diagnostics Market, By Product

• 5.1 Reagents & Kits
• 5.2 Instruments
• 5.3 Software & Services

6 Global Molecular Diagnostics Market, By Technology

• 6.1 Polymerase Chain Reaction (PCR)
• 6.2 Isothermal Nucleic Acid Amplification (INAAT)
• 6.3 Next-Generation Sequencing (NGS)
• 6.4 Sanger Sequencing
• 6.5 Microarrays
• 6.6 In Situ Hybridization (ISH)
• 6.7 Transcription-Mediated Amplification (TMA)
• 6.8 CRISPR-Based Molecular Diagnostics

7 Global Molecular Diagnostics Market, By Analyte

• 7.1 DNA
• 7.2 RNA
• 7.3 DNA & RNA

8 Global Molecular Diagnostics Market, By Test Type

• 8.1 Qualitative Tests
• 8.2 Quantitative Tests

9 Global Molecular Diagnostics Market, By Sample Type

• 9.1 Blood
• 9.2 Plasma & Serum
• 9.3 Tissue
• 9.4 Urine
• 9.5 Saliva
• 9.6 Nasopharyngeal & Oropharyngeal Swabs
• 9.7 Sputum
• 9.8 Stool
• 9.9 Cerebrospinal Fluid (CSF)
• 9.10 Other Clinical Specimens

10 Global Molecular Diagnostics Market, By Testing Location

• 10.1 Central Laboratory Testing
• 10.2 Point-of-Care (POC) Testing
• 10.3 Home-Based Testing

11 Global Molecular Diagnostics Market, By Application

• 11.1 Infectious Disease Diagnostics
• 11.2 Oncology
• 11.3 Genetic Disease Testing
• 11.4 Reproductive Health Testing
• 11.5 Blood Screening
• 11.6 Pharmacogenomics
• 11.7 Neurological Disorders
• 11.8 Cardiovascular Diseases
• 11.9 Respiratory Diseases
• 11.10 Gastrointestinal Diseases
• 11.11 Endocrine & Metabolic Disorders
• 11.12 Transplant Diagnostics
• 11.13 Other Clinical Applications

12 Global Molecular Diagnostics Market, By End User

• 12.1 Hospitals
• 12.2 Clinical Laboratories
• 12.3 Reference Laboratories
• 12.4 Diagnostic Centers
• 12.5 Academic & Research Institutes
• 12.6 Pharmaceutical & Biotechnology Companies
• 12.7 Contract Research Organizations (CROs)
• 12.8 Public Health Laboratories
• 12.9 Blood Banks
• 12.10 Other End Users

13 Global Molecular Diagnostics Market, By Geography

• 13.1 North America
  • 13.1.1 United States
  • 13.1.2 Canada
  • 13.1.3 Mexico
• 13.2 Europe
  • 13.2.1 United Kingdom
  • 13.2.2 Germany
  • 13.2.3 France
  • 13.2.4 Italy
  • 13.2.5 Spain
  • 13.2.6 Netherlands
  • 13.2.7 Belgium
  • 13.2.8 Sweden
  • 13.2.9 Switzerland
  • 13.2.10 Poland
  • 13.2.11 Rest of Europe
• 13.3 Asia Pacific
  • 13.3.1 China
  • 13.3.2 Japan
  • 13.3.3 India
  • 13.3.4 South Korea
  • 13.3.5 Australia
  • 13.3.6 Indonesia
  • 13.3.7 Thailand
  • 13.3.8 Malaysia
  • 13.3.9 Singapore
  • 13.3.10 Vietnam
  • 13.3.11 Rest of Asia Pacific
• 13.4 South America
  • 13.4.1 Brazil
  • 13.4.2 Argentina
  • 13.4.3 Colombia
  • 13.4.4 Chile
  • 13.4.5 Peru
  • 13.4.6 Rest of South America
• 13.5 Rest of the World (RoW)
  • 13.5.1 Middle East
    • 13.5.1.1 Saudi Arabia
    • 13.5.1.2 United Arab Emirates
    • 13.5.1.3 Qatar
    • 13.5.1.4 Israel
    • 13.5.1.5 Rest of Middle East
  • 13.5.2 Africa
    • 13.5.2.1 South Africa
    • 13.5.2.2 Egypt
    • 13.5.2.3 Morocco
    • 13.5.2.4 Rest of Africa

14 Strategic Market Intelligence

• 14.1 Industry Value Network and Supply Chain Assessment
• 14.2 White-Space and Opportunity Mapping
• 14.3 Product Evolution and Market Life Cycle Analysis
• 14.4 Channel, Distributor, and Go-to-Market Assessment

15 Industry Developments and Strategic Initiatives

• 15.1 Mergers and Acquisitions
• 15.2 Partnerships, Alliances, and Joint Ventures
• 15.3 New Product Launches and Certifications
• 15.4 Capacity Expansion and Investments
• 15.5 Other Strategic Initiatives

16 Company Profiles

• 16.1 F. Hoffmann-La Roche Ltd.
• 16.2 Thermo Fisher Scientific Inc.
• 16.3 Abbott Laboratories
• 16.4 Danaher Corporation
• 16.5 Bio-Rad Laboratories, Inc.
• 16.6 QIAGEN N.V.
• 16.7 Siemens Healthineers AG
• 16.8 Hologic, Inc.
• 16.9 Becton, Dickinson and Company (BD)
• 16.10 Illumina, Inc.
• 16.11 Agilent Technologies, Inc.
• 16.12 Revvity, Inc.
• 16.13 bioMerieux SA
• 16.14 Sysmex Corporation
• 16.15 Seegene Inc.
• 16.16 Exact Sciences Corporation
• 16.17 Guardant Health, Inc.
• 16.18 DiaSorin S.p.A.